Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and
intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the …

Increasing evidence indicates that success of targeted therapies in the treatment of cancer is
context-dependent and is influenced by a complex crosstalk between signaling pathways …

Background Optimal patient selection for neoadjuvant chemotherapy prior to surgical
extirpation is limited by the inaccuracy of contemporary clinical staging methods in high-risk …

Precision medicine has transformed the way urothelial carcinoma is managed. However,
current practices are limited by the availability of tissue samples for genomic profiling and …

Context While upper tract urothelial carcinoma (UTUC) share histological appearance with
bladder cancer (BC), the former has differences in etiology and clinical phenotype consistent …

Context Bladder and kidney cancers require invasive procedures for definitive diagnosis,
and bladder cancer requires repeated procedures to monitor for disease recurrence. Given …

Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive “liquid biopsy”
tool in precision medicine. ctDNA-genomic DNA fragments that are released into the …

Background Urothelial carcinoma (UC) is a common malignancy with significant associated
mortality. Recent clinical trials suggest an emerging role for HER2-targeted therapy. Testing …

Background ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in
patients with previously treated locally advanced/unresectable or metastatic urothelial …

Bladder cancer is a heterogeneous disease. Interpatient heterogeneity in response to a drug
limits treatment options and impairs improvement of patient survival. For example …